Novel MAPK/AKT-impairing germline NRAS variant identified in a melanoma-prone family - Brown, Kevin M.; Xu, Mai; Sargen, Michael; Jang, Hyunbum; Zhang, Mingzhen; Zhang, Tongwu; Zhu, Bin; Jones, Kristie; Kim, Jung; Mendoza, Laura; Hayward, Nicholas K.; Tucker, Margaret A.; et al. (medRxiv, 2021)
While several high-penetrance melanoma risk genes are known, variation in these genes fail to explain melanoma susceptibility in a large proportion of high-risk families. As part of a melanoma family sequencing study, including 435 families from Mediterranean populations, we identified a novel NRAS variant (c.170A>C, p.D57A) in a melanoma-prone family. This variant is absent in exomes in gnomAD, ESP, UKBiobank, and the 1000 Genomes Project, as well as in 11 273 Mediterranean individuals and 109 melanoma-prone families from the US and Australia. This variant occurs in the GTP-binding pocket of NRAS. Differently from other RAS activating alterations, NRAS D57A expression is unable to activate MAPK-pathway both constitutively and after stimulation but enhances EGF-induced PI3K-pathway signaling in serum starved conditions in vitro. Consistent with in vitro data demonstrating that NRAS D57A does not enrich GTP binding, molecular modeling suggests that the D57A substitution would be expected to impair Mg2+ binding and decrease nucleotide-binding and GTPase activity of NRAS. While we cannot firmly establish NRAS c.170A>C (p.D57A) as a melanoma susceptibility variant, further investigation of NRAS as a familial melanoma gene is warranted.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Dr. Stewart reports personal fees from Genome Medical, LLC, outside the submitted work. Dr. Peris reports personal fees from Abbvie, Almirall, Lilly, Galderma, Leo Pharma, Pierre Fabre, Novartis, Sanofi, Sun Pharma, and Janssen, outside the submitted work. Professor Stratigos reports personal fees and/or research support from Novartis, Roche, BMS, Abbvie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Dr. Puig reports grants from National Cancer Institute, grants from European Union Network of Excellent 6th Framework Program, grants from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, grants from Agency for Management of University and Research Grants, Catalan Government, during the conduct of the study; grants, personal fees and non-financial support from Almirall, funding to organize course from Avene, personal fees from BMS, Bioderma, and Cantabria, grants and courses from AMGEN, grants, personal fees and non-financial support from ISDIN, grants, personal fees and funding to organize course from La Roche Posay, grants, personal fees and training from Novartis, personal fees and funding to organize courses from Roche, personal fees from Sanofi, grants, personal fees, and funding to organize courses from Sun Pharma, personal fees from Regeneron, grants and personal fees from Leo Pharma, non-financial support and equipment from Abbvie, non-financial support and funding to organize courses from Canfield, non-financial support from 3Gen, personal fees and funding to organize courses from Fotofinder, funding to organize course from MAVIG, instruments for research from MEdea, outside the submitted work.Funding StatementThis research was supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute, Division of Cancer Epidemiology and Genetics (ZIACP010201 for KMB, ZIACP101231 for MTL, and ZIACP010144 for MS; https://dceg.cancer.gov/) and Center for Cancer Research (ZIABC010442 for RN; https://ccr.cancer.gov/) and the National Health and Medical Research Council of Australia (1117663 for NKH; https://www.nhmrc.gov.au). This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN26120080001E.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This overall study was approved by IRB at the National Cancer Institute, as well as local institutions.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings will be available in dbGaP at https://www.ncbi.nlm.nih.gov/gap/ following a 6-month embargo from the date of publication of the article in a peer-reviewed journal.